Drug
Serlopitant clinical trials
Also written VPD-737.
- studies test it
- 13
- open now
- 0
- in phase 3
- 3
- first study started
- 2006
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 10
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 2
Vyne Therapeutics Inc. (11) · Stanford University (1) · Jean Yuh Tang (1)
Studies
Open first, then newest update. How each study uses serlopitant is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis BullosaCompletedPhase 2Stanford UniversityNCT03836001Written as Serlopitant Tablet
- VPD-737 for Treatment of Chronic PruritusCompletedPhase 2Vyne Therapeutics Inc.NCT01951274Written as VPD-737
- Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown OriginCompletedPhase 2Vyne Therapeutics Inc.NCT03841331Written as 5 mg Serlopitant Tablets
- Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic CoughCompletedPhase 2Vyne Therapeutics Inc.NCT03282591Written as 5 mg Serlopitant Tablets
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisCompletedPhase 3Vyne Therapeutics Inc.NCT03677401Written as 5mg Serlopitant Tablets
- A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)CompletedPhase 2Vyne Therapeutics Inc.NCT02196324Written as serlopitant
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisCompletedPhase 3Vyne Therapeutics Inc.NCT03546816Written as 5mg Serlopitant Tablets
- Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque PsoriasisCompletedPhase 2Vyne Therapeutics Inc.NCT03343639Written as 5 mg Serlopitant Tablets
- Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)TerminatedPhase 3Vyne Therapeutics Inc.NCT03540160Written as 5 mg Serlopitant Tablets
- A Study of MK0594 in Patients With Alcohol Dependence (0594-020)TerminatedPhase 2Vyne Therapeutics Inc.NCT00835718Written as Comparator: MK0594 5 mg/day
- Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn InjuryTerminatedPhase 2Vyne Therapeutics Inc.NCT02975271Written as Serlopitant
- Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)CompletedPhase 2Vyne Therapeutics Inc.NCT00290563Written as MK0594
- Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB PatientsCompletedPhase 2Jean Yuh TangNCT02654483Written as VPD-737
Codes
What other systems call serlopitant · ClinicalTrials.gg INT005688
- MeSH (NLM) C551592serlopitantConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 277V92K32BSERLOPITANTConfirmed FDA, NLM, Wikidata
- Wikidata Q21098912serlopitantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81499SerlopitantOne source FDA
- DrugBank DB12973One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C551592 | serlopitant | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 277V92K32B | SERLOPITANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q21098912 | serlopitant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81499 | Serlopitant | One source FDA |
| DrugBank | DB12973 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.